Top Markets
#1 MowCat MowCat +49.01%
#2 Velvet Velvet +26.59%
#3 Bermuda Shorts Bermuda Shorts +25.22%
#4 Biconomy Biconomy +21.45%
#5 Derive Derive +20.93%
#6 Audiera Audiera +19.36%
#7 Quack AI Quack AI +19.08%
#8 aPriori aPriori +18.64%
#9 Perle Perle +12.16%
#10 DODO DODO +11.93%
Coin of the day
MowCat MowCat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Medigene AG Medigene AG

Medigene AG

MDG1
Classement en actions #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Prix de l'action
$0.14942078
Dernière synchronisation: 2025-05-15
Capitalisation boursière
$3.86M
Changement (1 jour)
0.10%
Changement (1 an)
0.00%
Pays
DE
Échange Medigene AG (MDG1)

Catégorie

Healthcare
Ratio P/S pour Medigene AG (MDG1)
Ratio P/S au August 2026 TTM : 0.33
Selon les derniers rapports financiers et le cours de l'action de Medigene AG, le ratio cours/ventes actuel (TTM) est 0.33. À la fin de 2022, le ratio P/S était de 1.58.
Historique du ratio P/S pour Medigene AG de 2004 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 0.33 -94.44%
2023 5.86 270.74%
2022 1.58 -76.40%
2021 6.70 -37.67%
2020 10.75 15.55%
2019 9.30 -81.25%
2018 49.61 -30.09%
2017 70.97 -38.41%
2016 115.23 29.31%
2015 89.11 1,204.14%
2014 6.83 -18.93%
2013 8.43 -29.80%
2012 12.01 -23.25%
2011 15.64 -52.41%
2010 32.87 915.33%
2009 3.24 -25.83%
2008 4.36 -43.78%
2007 7.76 51.85%
2006 5.11 -35.56%
2005 7.93 -16.62%
2004 9.52 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 3,018.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 3,006.19%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 1,354.31%
BE